From Name

From Email

To Name

To Email

Message

Triplet regimen shows 'substantial survival benefit' in breast cancer

from HemOnc Today

Triplet regimen shows 'substantial survival benefit' in breast cancer HemOnc Today Tucatinib in combination with trastuzumab and capecitabin showed a decreased risk for intracranial progression by two-thirds and reduced risk for death by nearly half in patients with heavily previously treated HER2-positive metastatic brain cancer with brain metastases, according to research presented at the ASCO 2020 Virtual Meeting. READ MORE

more